Cellectis to Report Q3 Results on November 12
The genome engineering company will release third quarter 2026 financial results after U.S. market close and host an investor call the following day.
Updated on Nov. 9, 2026 in Biotech
Cellectis, a genome engineering company developing genetic medicines, will report its third quarter 2026 financial results on November 12, 2026, after the close of the U.S. market. The company will follow with an investor conference call and webcast on November 13, 2026.
Why it matters
The reporting date and accompanying investor call give shareholders and market watchers a scheduled opportunity to review the company's quarterly performance. Cellectis is listed on both the Nasdaq Global Market and Euronext Growth, so the release reaches investors in multiple markets.
The announcement covers results for the third quarter ending September 30, 2026, with the release set for November 12, 2026. The financial figures, and how they compare to prior quarters, will not be known until the company publishes them.
The players
Cellectis
Cellectis is a genome engineering company based in Paris that develops genetic medicines and is listed on the Nasdaq Global Market under the ticker CLLS.
The details
Cellectis will publish its results after the U.S. market closes on November 12, then hold an investor conference call and webcast at 8:00 a.m. ET on November 13. The company is headquartered in Paris, France, with additional locations in New York and Raleigh, North Carolina.
Timeline
November 12, 2026: Cellectis reports third quarter 2026 results after U.S. market close.
November 13, 2026, 8:00 a.m. ET: Cellectis hosts its investor conference call and webcast.
Big Picture
Cellectis's scheduled third quarter release follows the standard quarterly disclosure cycle that publicly listed biotechnology companies observe. The announcement is a routine marker in that cycle rather than a change to it.
Investors and shareholders can plan to review the third quarter financial results and the subsequent call on the announced dates. The disclosures will show the company's quarterly financial position for those following its Nasdaq or Euronext Growth listings.
The takeaway
Tracking scheduled earnings dates helps readers follow a company's financial disclosures on a predictable timeline. For Cellectis shareholders, the November 12 release and November 13 call are the key dates to watch.
What happens next
Cellectis will report its third quarter 2026 financial results on November 12, 2026, and hold its investor conference call on November 13, 2026.
Further reading
Explore more Biotech developments shaping the genetic medicine industry.
